When In Vitro Data Can Replace In Vivo Studies in ANDA Submissions

Understanding In Vitro and In Vivo Requirements

Generic drug applicants must demonstrate bioequivalence to a Reference Listed Drug (RLD) as part of an Abbreviated New Drug Application (ANDA). This bioequivalence can be shown through either:

• In vivo data — typically from pharmacokinetic (PK) studies in human volunteers
• In vitro data — such as comparative dissolution testing, where specific conditions are met

The U.S. FDA allows for waiver of in vivo studies in certain cases, especially for immediate-release solid oral dosage forms meeting Biopharmaceutics Classification System (BCS) criteria. This is commonly referred to as a biowaiver.

This article outlines when and how in vitro data may substitute in vivo studies in ANDA submissions, what regulatory guidance applies, and how to prepare a robust data package.

Biopharmaceutics Classification System (BCS) Overview

The BCS categorizes drugs based on solubility and permeability:

In general, Class I and Class III drugs may be eligible for biowaivers if rapid dissolution and other conditions are met. FDA’s Product-Specific Guidances (PSGs) often clarify when in vitro data is sufficient.

Dissolution Testing and the f₂ Similarity Factor

Comparative dissolution is key to in vitro bioequivalence. Testing is conducted in:

• pH 1.2 (simulated gastric fluid)
• pH 4.5 (simulated intestinal fluid)
• pH 6.8 (phosphate buffer)

A minimum of 12 units of test and reference products must be tested using USP Apparatus I or II.

Results are analyzed using the f₂ similarity factor, calculated as:

f₂ = 50 × log {[1 + (1/n) ∑(Rt – Tt)²]⁻⁰·⁵ × 100}
        

Where:

• n = number of time points
• Rt and Tt = % dissolved of reference and test at time t

An f₂ value between 50 and 100 indicates similarity.

Biowaiver Justification, Case Examples, and Regulatory Considerations

Justifying a Biowaiver in ANDA Submissions

To seek a biowaiver, the ANDA applicant must provide detailed evidence that the test product meets the criteria for waiver of in vivo studies. This includes:

• BCS classification evidence (solubility and permeability studies or literature)
• Formulation sameness or similarity to the RLD
• Manufacturing process control and batch uniformity
• Comparative dissolution data at three pH levels

For BCS Class III drugs, additional criteria include demonstrating excipient sameness (Q1/Q2 similarity) and robust control of manufacturing variability.

In Vitro-In Vivo Correlation (IVIVC)

In some cases, in vitro data can be correlated to in vivo absorption using IVIVC models. While rarely required in ANDA submissions, IVIVC can strengthen biowaiver justification and support formulation bridging for post-approval changes.

IVIVC is most applicable to modified-release dosage forms and involves plotting in vitro release against in vivo absorption to determine Level A, B, or C correlations.

Real-World Example: BCS Class I Generic Approval

A sponsor developing a generic for a BCS Class I antihypertensive drug submitted:

• Evidence of high solubility across pH 1–7.5
• Human permeability data from published literature
• Comparative dissolution f₂ ≥ 65 at all pH levels

FDA accepted the biowaiver, and the product was approved without an in vivo PK study.

In Vivo Study Requirements for Non-Biowaivable Products

For BCS Class II and IV products or those with narrow therapeutic index (NTI), FDA typically requires in vivo studies. These include:

• Single-dose crossover design in healthy volunteers
• Fed and fasting conditions, if required
• PK endpoints: C_max, AUC_0–t, AUC_0–∞
• Statistical confidence interval (CI) of 80–125%

FDA guidance is available in the relevant PSGs and must be strictly followed.

Regulatory Pitfalls and Deficiencies

Common mistakes in biowaiver requests include:

• Inadequate f₂ justification (less than 12 units tested)
• Mismatch in formulation composition (Q1/Q2 differences)
• Incomplete permeability classification evidence
• Use of outdated dissolution methods or unvalidated equipment

These issues can lead to FDA issuing a Complete Response Letter (CRL), delaying approval and requiring additional in vivo data.

Role of Product-Specific Guidances (PSGs)

The FDA regularly updates its PSGs, which clarify whether in vitro-only data is acceptable. Applicants should always reference the latest guidance on:

• Study design requirements
• Waiver eligibility
• Dissolution media and apparatus

See the full list at FDA Product-Specific Guidances.

Conclusion: Strategic Use of In Vitro Data

Leveraging in vitro data in place of in vivo studies can significantly reduce development costs and timelines for generic drug sponsors. However, a successful biowaiver requires scientific justification, regulatory alignment, and rigorous testing.

In vitro strategies are especially beneficial for BCS Class I and III drugs. Applicants must ensure compliance with FDA’s biowaiver guidance and PSGs to avoid unnecessary rejections or clinical study requirements.